Aardvark Therapeutics (NASDAQ:AARD) Upgraded by Wall Street Zen to “Hold” Rating
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Friday. Other analysts also recently issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 price objective on shares […]
Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Friday. Other analysts also recently issued reports about the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 price objective on shares […]
